Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: BRCA1/2 Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Identifying and Caring for Individuals With Inherited Cancer Syndrome

NCT04494945
View directory record Official record
Conditions
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome, Breast Ductal Carcinoma In Situ, Hematopoietic and Lymphoid System Neoplasm, Hereditary Neoplastic Syndrome, Lynch Syndrome, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Genetic Counseling, Genetic Testing, Survey Administration
Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 1:32 PM EDT
Terminated Phase 2 Interventional

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

NCT03442556
View directory record Official record
Conditions
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Rucaparib Camsylate, Rucaparib
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jul 22, 2026, 1:32 PM EDT
Recruiting Phase 2 Interventional

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

NCT05806515
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Chest Radiography, Computed Tomography, Magnetic Resonance Imaging, PSMA PET Scan, Surgical Procedure
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
133
States / cities
Anchorage, Alaska • Phoenix, Arizona • Arroyo Grande, California + 96 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 22, 2026, 1:32 PM EDT
Terminated Phase 1 Interventional

First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

NCT06625515
View directory record Official record
Conditions
Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer, Rectal Adenocarcinoma, Endometrial Cancer
Interventions
ATX-559
Drug
Lead sponsor
Accent Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Aurora, Colorado • Oklahoma City, Oklahoma • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jul 22, 2026, 1:32 PM EDT
Completed No phase listed Observational

Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families

NCT03119285
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Jul 22, 2026, 1:32 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

BRCA1/2 Flu Vaccine

NCT04499534
View directory record Official record
Conditions
BRCA1 Mutation, BRCA2 Mutation
Interventions
Seasonal influenza vaccine
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
25 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 1:32 PM EDT
Recruiting Phase 3 Interventional

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

NCT06580314
View directory record Official record
Conditions
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Bevacizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Biological · Procedure · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
658
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 447 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 22, 2026, 1:32 PM EDT
Terminated Phase 2 Interventional Results available

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

NCT02326844
View directory record Official record
Conditions
Ovarian Cancer
Interventions
BMN 673 (talazoparib)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Jul 22, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT01540565
View directory record Official record
Conditions
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Epithelial Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Laboratory Biomarker Analysis, Veliparib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
153
States / cities
Phoenix, Arizona • Concord, California • La Jolla, California + 114 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Jul 22, 2026, 1:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adaptation to Living With a BRCA1/2 Mutation

NCT01866865
View directory record Official record
Conditions
Cancer Genetics
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jul 22, 2026, 1:32 PM EDT
Recruiting No phase listed Observational

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk

NCT02478892
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Collection of data from endoscopic ultrasound or MRI/MRCP of the abdomen, Blood sample collection for research
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 1:32 PM EDT
Terminated Phase 1Phase 2 Interventional

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

NCT06065059
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer
Interventions
TNG348, Olaparib
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Denver, Colorado • Orange City, Florida • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Jul 22, 2026, 1:32 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)

NCT02034916
View directory record Official record
Conditions
Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions
talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
37
States / cities
Greenbrae, California • Los Angeles, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2019 · Synced Jul 22, 2026, 1:32 PM EDT
Completed Phase 1 Interventional

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

NCT02482311
View directory record Official record
Conditions
Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
Interventions
AZD 1775
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
Fayetteville, Arkansas • San Francisco, California • West Hollywood, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Jul 22, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

NCT01525589
View directory record Official record
Conditions
Breast Cancer
Interventions
PM01183
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
5
States / cities
Stanford, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Jul 22, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

NCT03845296
View directory record Official record
Conditions
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma, Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Rucaparib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
950
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 630 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jul 22, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility

NCT02133703
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
Enhanced Internet DA, Internet DA, Enhanced Print DA, Print DA, Inconclusive Results DA
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Jul 22, 2026, 1:32 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

NCT05787587
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC
Interventions
IDE-161, Pembrolizumab
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 22, 2026, 1:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lessons Learned From the Family Gene Toolkit

NCT02154633
View directory record Official record
Conditions
Women With BRCA 1 or BRCA 2 Mutation, Non-tested Female Family Members
Interventions
Family Gene Toolkit, Delayed Family Gene Toolkit
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Jul 22, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

NCT02401347
View directory record Official record
Conditions
Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer
Interventions
Talazoparib Tosylate
Drug
Lead sponsor
Melinda Telli
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jul 22, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

NCT02282020
View directory record Official record
Conditions
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions
OLAPARIB, Single agent chemotherapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jul 22, 2026, 1:32 PM EDT
Completed Phase 1 Interventional

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04991480
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Breast Cancer
Interventions
ART4215, Talazoparib, Niraparib
Drug
Lead sponsor
Artios Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
New Haven, Connecticut • Orlando, Florida • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 22, 2026, 1:32 PM EDT
Terminated Phase 2 Interventional Results available

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

NCT03140670
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
RUCAPARIB
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jul 22, 2026, 1:32 PM EDT
Completed No phase listed Observational Results available

Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk

NCT04257474
View directory record Official record
Conditions
Breast Cancer
Interventions
Self-Report Survey, Qualitative Interviews
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
25 Years to 85 Years · Female only
Enrollment
265 participants
Timeline
2020 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Jul 22, 2026, 1:32 PM EDT